AR085236A1 - Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d - Google Patents
Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty dInfo
- Publication number
- AR085236A1 AR085236A1 ARP120100497A ARP120100497A AR085236A1 AR 085236 A1 AR085236 A1 AR 085236A1 AR P120100497 A ARP120100497 A AR P120100497A AR P120100497 A ARP120100497 A AR P120100497A AR 085236 A1 AR085236 A1 AR 085236A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- heterocycloalkyl
- cycloalkyl
- alkoxy
- Prior art date
Links
- LEEAWDCJRIAXFL-UHFFFAOYSA-N N1CCNCC1.O1COC2=C1C=CC=C2 Chemical class N1CCNCC1.O1COC2=C1C=CC=C2 LEEAWDCJRIAXFL-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos moduladores duales de los receptores de la 5-HT2A y de la D3, compuestos, composiciones farmacéuticas que los contienen y su utilización como medicamentos.Reivindicación 1: Compuestos de la fórmula (1) en la que: n es el número 0, 1, 2 ó 3; Y es -C(O)- o -S(O)2-; R1 es hidrógeno, halógeno, ciano, alquilo, haloalquilo, hidroxi, alcoxi, haloalcoxi, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, -NR7R8, -C(O)-NR7R8 o -S(O)2-R7; dichos alquilo, haloalquilo y alcoxi están opcionalmente sustituidos por uno, dos o tres restos independientes R5; y dichos cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos por uno, dos o tres restos independientes R6; R2, R3, R4 son con independencia hidrógeno, halógeno, alquilo, haloalquilo, hidroxi, alcoxi o haloalcoxi; R5 es ciano, hidroxi, alcoxi, cicloalquilo, heterocicloalquilo, arilo o heteroarilo, dichos cicloalquilo, heterocicloalquilo arilo y heteroarilo están opcionalmente sustituido por uno, dos o tres restos independientes R6; R6 es halógeno, ciano, alquilo, haloalquilo, hidroxialquilo, hidroxi, alcoxi, haloalcoxi, oxo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo; R7, R8 son con independencia hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, arilo, arilo sustituido por halógeno o heteroarilo; las sales y ésteres farmacéuticamente aceptables de los mismos; y los análogos deuterados de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11154780 | 2011-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085236A1 true AR085236A1 (es) | 2013-09-18 |
Family
ID=45722618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100497A AR085236A1 (es) | 2011-02-17 | 2012-02-15 | Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8722683B2 (es) |
| EP (1) | EP2675798B1 (es) |
| JP (1) | JP2014505715A (es) |
| KR (1) | KR20140006953A (es) |
| CN (1) | CN103380122B (es) |
| AR (1) | AR085236A1 (es) |
| AU (1) | AU2012217150A1 (es) |
| BR (1) | BR112013020656A2 (es) |
| CA (1) | CA2823988A1 (es) |
| CO (1) | CO6761304A2 (es) |
| CR (1) | CR20130318A (es) |
| EA (1) | EA201391124A1 (es) |
| EC (1) | ECSP13012838A (es) |
| ES (1) | ES2546430T3 (es) |
| MA (1) | MA34946B1 (es) |
| MX (1) | MX2013008531A (es) |
| PH (1) | PH12013501462A1 (es) |
| SG (1) | SG192819A1 (es) |
| WO (1) | WO2012110470A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| KR20200112910A (ko) | 2018-01-26 | 2020-10-05 | 시오노기 앤드 컴파니, 리미티드 | 도파민 d3 수용체 길항 작용을 갖는 축환 화합물 |
| CN111770754B (zh) * | 2019-01-30 | 2023-09-19 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| CN110372557B (zh) * | 2019-08-06 | 2021-05-18 | 上海勋和医药科技有限公司 | 环己烷胺类d3/d2受体部分激动剂 |
| BR112022007238A2 (pt) * | 2019-10-29 | 2022-07-05 | Shanghai Hansoh Biomedical Co Ltd | Compostos modificadores derivados de anel de quatro membros, métodos para preparar os referidos compostos, composição e uso |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3347381B2 (ja) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | ペットフード |
| WO1996039133A1 (en) | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| EP1683790A1 (en) * | 2005-01-24 | 2006-07-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| RU2396265C2 (ru) | 2006-02-17 | 2010-08-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3 |
| BRPI0718127A2 (pt) * | 2006-10-31 | 2014-02-18 | Hoffmann La Roche | Moduladores duais de derivados de éter dos receptores de 5-ht2a e d3 |
| KR101169518B1 (ko) * | 2007-07-26 | 2012-07-27 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ2ａ 및 ｄ3 수용체의 이중 조절제 |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| AU2009294695B2 (en) * | 2008-09-22 | 2012-09-13 | F. Hoffmann-La Roche Ag | Piperazine D3 and 5-HT2a receptor modulators |
| AU2009296047A1 (en) * | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors |
| US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8598357B2 (en) * | 2011-03-03 | 2013-12-03 | Hoffmann-La Roche Inc. | Benzodioxole piperidine compounds |
-
2012
- 2012-02-10 US US13/370,345 patent/US8722683B2/en not_active Expired - Fee Related
- 2012-02-14 MA MA36210A patent/MA34946B1/fr unknown
- 2012-02-14 EA EA201391124A patent/EA201391124A1/ru unknown
- 2012-02-14 CA CA2823988A patent/CA2823988A1/en not_active Abandoned
- 2012-02-14 CN CN201280009057.7A patent/CN103380122B/zh not_active Expired - Fee Related
- 2012-02-14 ES ES12705101.9T patent/ES2546430T3/es active Active
- 2012-02-14 BR BR112013020656A patent/BR112013020656A2/pt not_active IP Right Cessation
- 2012-02-14 JP JP2013553896A patent/JP2014505715A/ja active Pending
- 2012-02-14 KR KR1020137024327A patent/KR20140006953A/ko not_active Withdrawn
- 2012-02-14 PH PH1/2013/501462A patent/PH12013501462A1/en unknown
- 2012-02-14 SG SG2013062443A patent/SG192819A1/en unknown
- 2012-02-14 WO PCT/EP2012/052440 patent/WO2012110470A1/en not_active Ceased
- 2012-02-14 AU AU2012217150A patent/AU2012217150A1/en not_active Abandoned
- 2012-02-14 MX MX2013008531A patent/MX2013008531A/es active IP Right Grant
- 2012-02-14 EP EP12705101.9A patent/EP2675798B1/en not_active Not-in-force
- 2012-02-15 AR ARP120100497A patent/AR085236A1/es not_active Application Discontinuation
-
2013
- 2013-06-21 CO CO13148386A patent/CO6761304A2/es not_active Application Discontinuation
- 2013-06-25 CR CR20130318A patent/CR20130318A/es unknown
- 2013-08-16 EC ECSP13012838 patent/ECSP13012838A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20130318A (es) | 2013-09-03 |
| CO6761304A2 (es) | 2013-09-30 |
| CA2823988A1 (en) | 2012-08-23 |
| MA34946B1 (fr) | 2014-03-01 |
| CN103380122B (zh) | 2015-04-29 |
| US8722683B2 (en) | 2014-05-13 |
| HK1189880A1 (en) | 2014-06-20 |
| ES2546430T3 (es) | 2015-09-23 |
| MX2013008531A (es) | 2013-08-12 |
| JP2014505715A (ja) | 2014-03-06 |
| KR20140006953A (ko) | 2014-01-16 |
| US20130040948A1 (en) | 2013-02-14 |
| EP2675798B1 (en) | 2015-07-01 |
| CN103380122A (zh) | 2013-10-30 |
| WO2012110470A1 (en) | 2012-08-23 |
| AU2012217150A1 (en) | 2013-05-02 |
| EP2675798A1 (en) | 2013-12-25 |
| PH12013501462A1 (en) | 2013-08-28 |
| SG192819A1 (en) | 2013-09-30 |
| BR112013020656A2 (pt) | 2016-10-18 |
| ECSP13012838A (es) | 2013-09-30 |
| EA201391124A1 (ru) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085236A1 (es) | Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR086828A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR071857A1 (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| UY30804A1 (es) | Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| ECSP10010473A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |